Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptomycin is an aminoglycoside antibiotic that functions as a protein synthesis inhibitor. It exerts its antibacterial effect by irreversibly binding to the 16S ribosomal RNA (rRNA) of the bacterial 30S ribosomal subunit. This binding interferes with the attachment of formyl-methionyl-tRNA, leading to misreading of the messenger RNA (mRNA) and premature termination of protein synthesis. The disruption of essential protein production ultimately results in bacterial cell death. Discovered in 1943 by Albert Schatz from the bacterium Streptomyces griseus, under the supervision of Selman Waksman, streptomycin was the first antibiotic found to be effective against tuberculosis. It is a broad-spectrum antibiotic active against various Gram-positive and Gram-negative bacteria, and is used to treat a range of bacterial infections including tuberculosis, plague, tularemia, brucellosis, and certain forms of endocarditis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on streptomycin.